 Aptoses second quarter update was undramatic, with management indicating that theyve fully enrolled their Phase I luxeptinib studies at 750mg and are moving on to 900mg. Dose escalation awaits in the APTO-253 AMLMDS study, but management is also going to start enrolling patients with certain eligible B-cell cancers. 